Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials

Chimeric antigen receptor (CAR) redirected T-cells has shown efficacy in the treatment of B-cell leukemia/lymphoma, however, high numbers of relapses occur due to loss of targeted antigen or intrinsic failure of the CAR T-cells. In this situation modifications of the basic strategy are envisaged to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ormhøj, Maria, Abken, Hinrich, Hadrup, Sine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463290/
https://www.ncbi.nlm.nih.gov/pubmed/35199207
http://dx.doi.org/10.1007/s00262-022-03163-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463290/
https://www.ncbi.nlm.nih.gov/pubmed/35199207
http://dx.doi.org/10.1007/s00262-022-03163-y

Ejemplares similares